CDC advisory meeting in March to focus on COVID-19 vaccine injuries, long COVID
Source: SeekingAlpha
2026-02-26 12:27:26 ET
More on Pfizer, BioNTech, etc.
- BioNTech: The Market Is Pricing Low Oncology Success
- Pfizer: A Risky 6.3% Yield For Income-Oriented Investors
- Q4 Healthcare Dividends: Johnson & Johnson Kept Outshining Pfizer (Rating Upgrades)
- Novavax posts Q4 revenue beat and net income for 2025
- NovavaxEPS of $0.11, revenue of $147.14M beats by $57.28M
Read the full article on Seeking Alpha
For further details see:
CDC advisory meeting in March to focus on COVID-19 vaccine injuries, long COVID
BioNTech SE
NASDAQ: BNTX
BNTX Trading
-20.41% G/L:
$80.30 Last:
8,115,591 Volume:
$82.81 Open:
BNTX Latest News
BNTX Stock Data
$26,377,590,776
95,508,380
N/A
104
N/A
Biotechnology & Life Sciences
Healthcare
DE
Mainz
